Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer
19. Oktober 2022 04:00 ET
|
AKAMPION
- Former Roche Head of Neuroimmunology strengthens Rewind´s neuroimmunology and neurodegeneration expertise Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics, a company developing...
HpVac Announces New Animal Data of its Lead Compound Demonstrating Protection Against Allergic Asthma
18. Oktober 2022 04:00 ET
|
AKAMPION
- Major milestone for accelerating the development of HpVac-13 in allergic diseases Geneva, Switzerland, October 18, 2022 – HpVac SA, a company developing novel preventive and therapeutic...
1ST Biotherapeutics, Inc., Announces Positive Phase I Data of c-Abl Inhibitor in Neurodegeneration
18. Oktober 2022 03:00 ET
|
AKAMPION
- Compound demonstrates excellent safety and tolerability in single ascending dose trial - Efficient penetration of blood-brain barrier YONGIN, South Korea, October 18, 2022 -- 1ST...
ImmunOs Therapeutics Appoints Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering
17. Oktober 2022 04:00 ET
|
AKAMPION
- Former Novartis director brings significant expertise in drug discovery and development Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 17, 2022 – ImmunOs Therapeutics...
InfanDx AG: Biomarker-Panels zur Früherkennung von hypoxisch-ischämischer Enzephalopathie erfolgreich validiert
12. Oktober 2022 05:00 ET
|
AKAMPION
Zahlreiche in der AAMBI-Studie identifizierte metabolische Biomarker in der BANON-Kohorte bestätigtPanel-Sensitivität von bis zu 89 % und Spezifität von bis zu 93 % in verblindeter...
InfanDx AG Reports Successful Validation of Biomarker Panels for the Early Detection of Hypoxic Ischemic Encephalopathy
12. Oktober 2022 05:00 ET
|
AKAMPION
Numerous metabolic biomarkers identified in AAMBI study confirmed in BANON cohortPanel sensitivities of up to 89% at specificities of up to 93% in blinded validation study Formal IVD development of...
ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors
04. Oktober 2022 04:00 ET
|
AKAMPION
- Seasoned immuno-oncology executive brings significant medical and biopharma expertise Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 4, 2022 – ImmunOs Therapeutics...
TolerogenixX Publishes Three-Year Follow-Up Data from Phase I Trial of Immune Tolerance-Inducing MIC-Lx Cell Therapy
26. September 2022 04:00 ET
|
AKAMPION
Publication in high-impact Journal of the American Society of NephrologyResults pave the way for a novel cell therapy in organ transplantation Heidelberg, September 26, 2022 – TolerogenixX...
InfanDx AG ernennt Nicole Witzmann zum Finanzvorstand
01. September 2022 05:00 ET
|
AKAMPION
- Corporate Finance Expertin mit mehr als acht Jahren Erfahrung im Gesundheitssektor Köln/Berlin, Deutschland, und Boston, USA, 01. September 2022 - Die InfanDx AG, ein privates...
InfanDx AG Appoints Nicole Witzmann as Chief Financial Officer
01. September 2022 05:00 ET
|
AKAMPION
Seasoned professional with more than 8 years of healthcare corporate finance experience Cologne/Berlin, Germany, and Boston, MA, USA, September 01, 2022 – InfanDx AG, a privately held...